ENDRA Life Sciences Inc
endrainc.comWhat Do They Do?
Develops a thermo-acoustic ultrasound platform for measuring liver fat, aimed at pharmaceutical companies and clinical research organizations, specialty clinics, and primary-care practices.
10-K for FY2025, filed Mar 31, 2026We were incorporated as a Delaware corporation in 2007. We are developing a next-generation enhanced ultrasound technology platform—Thermo-…View ↗
Our initial focus for the development and commercialization of TAEUS is a solution for the assessment of liver fat, a key biomarker…View ↗
For our go-to-market strategy, we intend to focus on serving these four markets:View ↗
Who Are Their Customers?
Plans to target pharmaceutical companies and clinical research organizations, plus high-end primary-care, bariatric and metabolic clinics and primary and internal medicine practices. It expects to sell directly, with partnerships and channel relationships supplementing direct sales over time.
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 14, 2026
$159.9KView ↗
- ▲ Now profitable
- vs −$1.2M in Q2 FY2025
-
Jul 9, 2026
Nasdaq said ENDRA regained compliance with its minimum equity requirement
Nasdaq will monitor the company’s listing-rule compliance for one year.
Sources
8-K, filed Jul 9, 2026
On July 8, 2026, the Company received written notice (the “Notice”) from Nasdaq indicating that the Company has regained compliance with…View ↗
-
Jun 26, 2026
ENDRA agreed to merge with Noble Africa
Under the agreement, Noble Africa would merge with an ENDRA subsidiary and survive as its wholly owned subsidiary.
Sources
8-K, filed Jun 26, 2026
On June 25, 2026, ENDRA Life Sciences Inc., a Delaware corporation (“ENDRA” or the “Company”), entered into an Agreement and Plan of Merger…View ↗
-
Apr 21, 2026
Nasdaq notified ENDRA it no longer met a continued-listing equity requirement
The company said a hearing request would pause further action on the possible delisting.
Sources
8-K, filed Apr 21, 2026
On April 20, 2026, the Staff issued a letter to the Company indicating that, because the Company’s stockholders’ equity as reported in its…View ↗
Preclinical system to TAEUS
The older report describes selling and later discontinuing a preclinical imaging system; the latest report centers on developing TAEUS for liver-fat assessment and metabolic disease.
10-K for FY2022, filed Mar 16, 2023 10-K for FY2025, filed Mar 31, 2026In 2010, we began marketing and selling our Nexus 128 system, which combined light-based thermoacoustics and ultrasound to address the…View ↗
Subscription model
The older report presents TAEUS as an accessory for existing ultrasound systems; the latest report plans multi-year subscriptions while retaining equipment sales.
10-K for FY2022, filed Mar 16, 2023 10-K for FY2025, filed Mar 31, 2026Because of the large number of traditional ultrasound systems currently in global use, we are first developing our TAEUS technology for…View ↗
We plan to offer a multi-year, subscription-based business model with recurring revenue, while continuing to support traditional capital…View ↗
Who Do They Compete With?
Competes with GE Healthcare, Royal Philips, Siemens Healthineers, Canon, Fujifilm, Cook Medical, Sterylab, Medtronic, and St. Jude Medical
10-K for FY2025, filed Mar 31, 2026Manufacturers of ultrasound and MRI systems include multi-national corporations such as GE Healthcare, Royal Philips, Siemens Healthineers…View ↗
Loading...
